Derajat Toksisitas Hemoglobin Pada Penderita Kanker Kolorektal Yang Mendapat Kemoterapi CapeOX

Abstract

Advances in the treatment and use of chemotherapy have been shown to improve the life expectancy rate for colorectal cancer patients. Studies conducted in China and Hongkong have shown that CapeOX combination chemotherapy regimens are more commonly used than in Europe and the United States. However, the use of chemotherapy drugs containing oxaliplatin and capecitabine can cause side effects such as hematological toxicity, which is one of them is anemia. This study aims to determine the difference in the form of a decrease in the average levels of hemoglobin and the degree of hemoglobin toxicity in colorectal cancer patients undergoing CapeOX chemotherapy. The Design in this study is a historical (retrospective) cohort. This study sample was 70 colorectal cancer patients who received CapeOX chemotherapy for 6 cycles at RSUD Dr. H. Abdul Moeloek in 2018-2019. Consecutive sampling is used in the sampling method. The statistical analysis is using Paired T-Test. There is a significant difference in the average hemoglobin level of colorectal cancer patients (p-value = <0.005), which receive CapeOX chemotherapy for 6 cycles. Besides, there is an increase in the number of patients who get hemoglobin toxicity and the chemotherapy cycle. In the first cycle, 59 patients (84.3%) got hemoglobin toxicity after chemotherapy, and the number continued to increase to 69 patients (98.6%) in the sixth cycle. There was a decrease in hemoglobin levels in colorectal cancer patients who received CapeOX chemotherapy with p-value = <0.05 and increased patients who got hemoglobin toxicity.

Grading Tumor Pasien Adenocarcinoma Colorectal di RS Dr. Hasan Sadikin Bandung Tahun 2015

“…Insidensi adenocarcinoma colorectal di Asia cukup tinggi, yaitu mencapai 957.896 kasus (51,8%) pada tahun 2018.2,3 Di Indonesia, adenocarcinoma colorectal merupakan kasus keganasan ketiga terbanyak dengan prevalensi usia pasien lebih muda dibanding dengan negara maju, yaitu sekitar lebih dari 30% kasus pasien berusia kurang dari 40 tahun. 4 Adenocarcinoma colorectal juga memiliki tingkat mortalitas sebesar 9,2% dan menjadi penyebab tertinggi kedua kematian akibat keganasan di dunia walaupun terdapat perbedaan di beberapa wilayah secara geografis.2 Insidensi adenocarcinoma colorectal di Rumah Sakit Dr. Hasan Sadikin Bandung pada tahun 2017 sebanyak 212 kasus.5 Angka mortalitas adenocarcinoma colorectal di Indonesia masih cukup tinggi mencapai 9,5% kematian akibat adenokarsinoma pada tahun 2018.6 World Health Organization (WHO) memperkirakan peningkatan insidensi sebesar 77% dan mortalitas sebesar 80% pada tahun 2030. 7 Faktor prognosis adenocarcinoma colorectal yang dapat memengaruhi kelangsungan hidup pasien dapat dibagi menjadi faktor demografis serta faktor klinis dan patologis.…”